Clinical OMICS

JAN-FEB 2018

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link:

Contents of this Issue


Page 47 of 51

Precision Medicine 46 Clinical OMICs January/February 2018 BGI Genomics and Sanguine BioSci- ences said they will partner to develop a database combining genomic and clinical data, with the goal of accel- erating patient recruitment for pre- cision medicine clinical trials. Their first project will entail a collaboration to help clinical trial developers access searchable whole-genome and elec- tronic medical record (EMR) data of more than 1,000 patients diagnosed with rheumatoid arthritis. The companies said their database will enable drug developers to recruit more homogeneous patient cohorts for clinical studies, increasing a trial's likelihood of success by reducing risk and cost. "The partnership with Sanguine will allow precise and efficient clini- cal trial enrollment, and will enhance BGI's overall solution to its biopharma partners," Charles Bao, Ph.D., general manager of BGI Genomics subsidiary BGI Americas, said in a statement. "Whole-genome sequencing provides the most comprehensive and unbi- ased genomic profiling that will max- imize the value of Sanguine's patient database." Bao added that BGI plans to carry out the sequencing will be performed on its own BGISEQ NGS platform— the first time, he said, that the plat- form will be used in a large-scale biopharma patient profiling project. According to the company website, BGI has two BGISEQ platforms. One is BGISEQ-500, a benchtop high-through- put sequencing solution designed to process two high-throughput chips in a single run, providing 200-Gb read output per run. When combined with optional automatic library preparation and sample loading instruments, BGI Genomics can carry out a complete analysis of samples from input to the final result in 24 hours. BGISEQ-50, launched in Novem- ber 2016, is a miniaturized sequencer designed for "basic" sequencing proj- ects in lab and clinical research, with a built-in independent sample reagent loading reservoir and full-automatic reagent needle penetration system. BGISEQ-50 is designed to operate normally even under a low-pressure environment at an altitude of more than a mile high, up to 3,000 meters (9,842 feet). According to BGI Genom- ics, an entire process, including sam- ple preparation, can be completed in 18 hours with the optional automatic sample preparation system. Both BGISEQ platforms apply com- binatorial probe-anchor synthesis (cPAS) chemistry by incorporating a fluorescent probe to a DNA anchor on DNA nanoballs, followed by BGI Genomics, Sanguine to Partner on Precision Medicine Trial Database Brotman Baty Institute for Precision Medicine Launches in Seattle A $50 million gift from Jeffrey and Su- san Brotman, and Pam and Dan Baty has funded the creation of the the Brotman Baty Institute for Precision Medicine, a joint effort of Seattle's UW Medicine, Fred Hutchinson Cancer Research Center, and Seattle Children's. Jay Shendure, Ph.D., M.D., professor of genome sciences at the University of Washington School of Medicine and an investigator of the Howard Hughes Medi- cal Institute, will direct the Institute. "We have only begun to understand how the approximately 3 billion letters in the human genome actively code all of the complexity in a human body and the role they play in determining our health," said Shendure. "There are exciting revolu- tions going on right now that are leading us toward a future where the ways we in- teract with the healthcare system will be highly tailored to who we are as individu- als, genetically and otherwise." Researchers at the Institute will focus on discoveries that will improve pa- tient outcomes while minimizing the harmful side effects of treatments and therapies. Among the institute's first projects is an effort to catalog the roughly 60,000 estimated pos- sible mutations of the BRCA1 and BRCA2 genes in order to iden- tify those that confer the greatest risk of breast cancer. n Oguzaral / Getty Images

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - JAN-FEB 2018